Study on Trastuzumab and Pertuzumab for Patients with HER2 Gene Amplified Tumors (MATCH - Subprotocol J)

Program Overview

This study is exploring how well the drugs trastuzumab and pertuzumab work together to treat cancers that have an increased number of HER2 genes, except for breast, gastric, and colorectal cancers. These drugs are a type of targeted therapy that attach to the HER2 protein on cancer cells, blocking signals that promote cell growth and marking the cells for destruction by the immune system. Trastuzumab is already used for certain HER2-positive cancers, and research suggests that using both drugs together might be more effective than using one alone.

Description

The main goal of this study is to see how many patients experience a reduction in their cancer with the combination of trastuzumab and pertuzumab. Researchers also want to know how many patients are alive and have no disease progression after six months of treatment. They will also study how long it takes for the disease to progress or for the patient to pass away. Additionally, the study will look for other markers that might predict how well the treatment works or why it might not work, using various tests and imaging.

Patients will receive pertuzumab and trastuzumab through an IV every three weeks, as long as the cancer does not progress and there are no severe side effects. Throughout the trial, patients will have regular scans, heart tests, and blood samples taken. After finishing the treatment, patients will have follow-up visits every three months for two years, then every six months for one year.

This study is part of the MATCH Screening Trial, which involves specific eligibility criteria and testing protocols. For more details, refer to the MATCH Screening Protocol (NCT02465060).

Eligibility Criteria

Locations